Prognostic and Diagnostic Testing in Onco-Haematological Diseases in the Era of Novel Therapies: Current Updates and Future Perspectives

Dear Colleagues,

The last decade has been characterized by a progressive shift in the treatment of onco-hematological malignancies from conventional radio- and chemotherapy to innovative and more personalized therapies, including those based on chimeric antigen receptor (CAR) T cells, bispecific T-cell engagers (BiTEs), and antibody–drug conjugates (ADCs). As a result, many patients achieve responses, including complete radiographical or pathological remission, thus implying that sensitive techniques need to be implemented to monitor minimal residual disease (MRD). Additionally, there is a need to assess whether the prognostic biomarkers and risk scoring systems that have been validated mainly in the chemo-immunotherapy era retain significance in the context of innovative and more personalized therapies.

For this to be conceivable, novel diagnostic and prognostic testing modalities have been developed mainly based on next-generation sequencing, digital droplet PCR, mass cytometry, and digital imaging to study both the tumor and the tumor microenvironment. Considerable data indicate, in fact, that the immune landscape of hematological malignancies defined through the integration of genomic, epigenomic, and transcriptomic data influence anti-tumor immune responses and patient outcomes.

Thus, the aim of this Special Issue is to provide a comprehensive overview of newly developed prognostic and diagnostic approaches and of their use in onco-hematology in the era of novel agents. Original research articles as well as reviews on these topics are welcomed.

Dr. Cristiana Carniti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.